<a href="https://www.fiercebiotech.com/medtech/caredx-expands-cancer-testing-260m-naveris-buy" hreflang="en">CareDx expands into cancer testing with $260M Naveris buy </a>
CareDx is expanding its focus into cancer diagnostics by acquiring Massachusetts-based biotech Naveris for up to $260 million, which includes a $160 million upfront payment and additional revenue milestones. This acquisition introduces Naveris' liquid biopsy platform, NavDx, which detects HPV-driven cancers more accurately, and is expected to significantly boost CareDx's revenue in the coming years.
CareDx's acquisition of Naveris for up to $260 million marks a strategic expansion into the oncology market, leveraging Naveris' NavDx liquid biopsy platform for early and accurate detection of HPV-driven cancers. This move not only diversifies CareDx's portfolio beyond transplant monitoring but also positions it to capitalize on the growing demand for precision oncology diagnostics, particularly in high-burden disease areas where repeat testing is critical. This acquisition could signal a lucrative investment opportunity as CareDx anticipates 30% to 40% annual revenue growth from this segment over the next three years.